Description
Lenvatinib is a potent inhibitor of multiple receptor tyrosine kinases, with IC₅₀ values of 22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively. It inhibits SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibits tumor growth in the human small cell lung cancer H146 xenograft model.
Lenvatinib is a potent inhibitor of multiple receptor tyrosine kinases, with IC₅₀ values of 22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively. It inhibits SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibits tumor growth in the human small cell lung cancer H146 xenograft model.
Alternate Name/Synonyms: 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; E7080
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 417716-92-8
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₁H₁₉ClN₄O₄
Molecular Weight: 426.85
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>35 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent inhibitor of multiple receptor tyrosine kinases
MDL Number: N/A
PubChem CID: 9823820
SMILES: COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
InChi: InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
InChi Key: WOSKHXYHFSIKNG-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |